We wouldn’t blame Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shareholders if they were a little worried about the fact that Douglas Fambrough, the Co-Founder recently netted about US$1.5m selling shares at an average price of US$26.17. Probably the most concerning element of the whole transaction is that the dump amounted to 83% of their entire holding.
The Last 12 Months Of Insider Transactions At Dicerna Pharmaceuticals
In fact, the recent sale by Douglas Fambrough was the biggest sale of Dicerna Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. So we know that an insider sold shares at around the present share price of US$23.28. While we don’t usually like to see insider selling, it’s more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it’s not too bad (but it’s still not a positive).
You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Insider Ownership of Dicerna Pharmaceuticals
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.8% of Dicerna Pharmaceuticals shares, worth about US$12m. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Dicerna Pharmaceuticals Insiders?
An insider hasn’t bought Dicerna Pharmaceuticals stock in the last three months, but there was some selling. And even if we look to the last year, we didn’t see any purchases. While insiders do own shares, they don’t own a heap, and they have been selling. So we’d only buy after careful consideration. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Dicerna Pharmaceuticals.
But note: Dicerna Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.